Collect Product
Product Details
Synonyms
GLP-1-R, GLP-1R, glucagon like peptide 1 receptor
Source
Human GLP1R Protein, Fc Tag (GLR-H5253) is expressed from human 293 cells (HEK293). It contains AA Ala 21 - Glu 139 (Accession # P43220-1).
Predicted N-terminus: Ala 21
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 40.2 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Human GLP1R Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS
The purity of Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) is more than 85% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) at 1 μg/mL (100 μL/well) can bind GLP-1R antibody with a linear range of 0.2-8 ng/mL (QC tested).
Protocol
Bioactivity-SPR
Anti-GLPR1 antibody immobilized on CM5 Chip can bind Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) with an affinity constant of 19.5 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) immobilized on CM5 Chip can bind GLP-1 (7-37) with an affinity constant of 1.90 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) on Protein A Biosensor, can bind GLP-1 (7-37) with an affinity constant of 2.6 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
User Reviews Publish Comment
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Glucagon-like peptide-1
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
13 Details
- Highest R&D Stage：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
